Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | CCR2 | P41597 | 7/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3149564 | 1.00 | F2 (0.45) | F2MAPK14POLBNFKB1PSMB5 | |
| SCHEMBL3155080 | 0.92 | PSMB5 (0.41) | F2POLBNFKB1PSMB5NFKB2 | |
| SCHEMBL3155074 | 0.92 | PSMB5 (0.41) | F2POLBNFKB1PSMB5NFKB2 | |
| SCHEMBL1433110 | 0.88 | MAPK14 (0.45) | F2MAPK14CCR2KDM4ECTSL | |
| SCHEMBL3146146 | 0.87 | CTSL (0.44) | NFKB1PSMB5NFKB2RELACTSL | |
| SCHEMBL3146114 | 0.87 | CTSL (0.44) | NFKB1PSMB5NFKB2RELACTSL | |
| SCHEMBL3149873 | 0.86 | ALDH1A1 (0.41) | F2NFKB1PSMB5NFKB2RELA | |
| SCHEMBL3149826 | 0.86 | ALDH1A1 (0.41) | F2NFKB1PSMB5NFKB2RELA | |
| SCHEMBL1432829 | 0.86 | NAMPT (0.45) | NFKB1PSMB5NFKB2RELACCR2 | |
| SCHEMBL1432832 | 0.86 | NAMPT (0.45) | NFKB1PSMB5NFKB2RELACCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100076015-A1 | Aminopyridine Derivatives | VANTIA LIMITED (GB) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076015-A1 | Aminopyridine Derivatives | CHRM1, ARG1, ARG2 | F2 1046/4885MAPK14 2952/4885POLB 1602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.